DelveInsight's "Narcolepsy Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Narcolepsy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Narcolepsy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Narcolepsy: An Overview
Narcolepsy is a chronic neurological/brain disorder that involves poor control of sleep and wakefulness. Narcolepsy is classically a tetrad of symptoms, including EDS, cataplexy, sleep paralysis, and hypnagogic hallucinations. People suffering from narcolepsy experience periods of excessive daytime sleepiness and sudden uncontrollable episodes of falling asleep at any time of the day. Rapid eye movement (REM) sleep tends to occur immediately in them. Narcolepsy may also be characterized by hallucinations, sleep paralysis, and cataplexy, which are partial or total loss of muscle control that is often triggered by a strong emotion. As per existing literature, it occurs in both men and women.
Approximately 70% of narcoleptic people have cataplexy, that is to say, a sudden - partial or total - fall in muscle tone, generally as a result of a pleasant emotion (type 1 narcolepsy). This event is associated with the risk of accidents, falls, and injuries. In addition to the negative impact of the disease on daily life, people with narcoleptics have difficulty concentrating and learning.
Narcolepsy Market Key Facts
-
As per Delveinsight’s estimates, the total prevalent population of Narcolepsy in the 7MM was 499,888 in 2017.
-
The total prevalent cases of Narcolepsy were highest in Japan, followed by the United States and Germany. France accounted for the least number of prevalent cases among the 7MM.
-
Among the European countries, Germany had the highest prevalent population of Narcolepsy, with 40,000 cases, followed by the United Kingdom, which had a prevalence of 30,000 in 2017. On the other hand, France had the lowest prevalent population of 16,777 cases in 2017.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Narcolepsy market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Narcolepsy market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Narcolepsy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Narcolepsy Epidemiology, Segmented as -
-
Diagnosed Prevalent Cases of Narcolepsy [2019–2032]
-
Age-group wise Prevalence of Narcolepsy [2019–2032]
-
Clinical Manifestations Associated with Narcolepsy [2019–2032]
-
Subtype-specific cases of Narcolepsy [2019–2032]
Narcolepsy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Narcolepsy market or expected to be launched during the study period. The analysis covers the Narcolepsy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Narcolepsy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Narcolepsy Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/narcolepsy-market
Narcolepsy Therapeutics Analysis
Several major pharma and biotech giants are developing therapies for Narcolepsy. Currently, Avadel Pharmaceuticals is leading the therapeutics market with its drug candidates in the most advanced stage of clinical development.
The Leading Players in the Narcolepsy Therapeutics Market Include:
-
Alkermes
-
Avadel Pharmaceuticals
-
Axsome Therapeutics, Inc.
-
Centessa Pharmaceuticals
-
Cephalon Inc.
-
ConSynance Therapeutics
-
Harmony Biosciences
-
Jazz Pharmaceuticals
-
KemPharm
-
NLS Pharmaceutics
-
Ono Pharma
-
Otsuka Pharmaceutical
-
Reset Therapeutics
-
Sunovion Pharmaceuticals
-
Suven Life Sciences
-
Takeda
-
Vallon Pharmaceuticals
-
XWPharma
And Many Others
Narcolepsy Emerging and Marketed Drugs Covered in the Report Include:
-
ADAIR: Vallon Pharmaceuticals
-
AXS-12: Axsome therapeutics
-
FT218: Avadel Pharmaceuticals
-
Mazindol CR: NLS Pharma
-
SUVN-G3031: Suven Life Sciences Limited
-
TAK-994: Takeda
And Many Others
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/narcolepsy-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Narcolepsy Competitive Intelligence Analysis
4. Narcolepsy Market Overview at a Glance
5. Narcolepsy Disease Background and Overview
6. Narcolepsy Patient Journey
7. Narcolepsy Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Narcolepsy Treatment Algorithm, Current Treatment, and Medical Practices
9. Narcolepsy Unmet Needs
10. Key Endpoints of Narcolepsy Treatment
11. Narcolepsy Marketed Products
12. Narcolepsy Emerging Drugs and Latest Therapeutic Advances
13. Narcolepsy Seven Major Market Analysis
14. Attribute Analysis
15. Narcolepsy Market Outlook (In US, EU5, and Japan)
16. Narcolepsy Access and Reimbursement Overview
17. KOL Views on the Narcolepsy Market
18. Narcolepsy Market Drivers
19. Narcolepsy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/narcolepsy-market
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Solutions
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
